ABIrateroneisananticancerchemotherapeuticcompoundthatisusedtotreatcastration-resistantprostatecancer.AbiratoneinhibitstheenzymeCytochromep45017α-hydroxylase(Cyp17),reducingandrogenproduction.ThiscompoundmayalsodirectlydecreaselevelsofandrogenreceptorproteinexpressionandinhibiteIF4Fsignaling.
| CasNo. | 154229-19-3 |
|---|---|
| Purity | ≥99% |
| Formula | C24H31NO |
| FormulaWt. | 349.51 |
| IUPACName | (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol |
| Solubility | MeOH |
| Appearance | Whitetooffwhitepowder |
| StoreTemp | Ambient |
|---|---|
| ShipTemp | Ambient |
| InfoSheet | A0534InfoSheetPDF |
|---|
RyanCJ,ChengML.Abirateroneacetateforthetreatmentofprostatecancer.ExpertOpinPharmacother.2013Jan;14(1):91-6.PMID:23199349.
RehmanY,RosenbergJE.Abirateroneacetate:oralandrogenbiosynthesisinhibitorfortreatmentofcastration-resistantprostatecancer.DrugDesDevelTher.2012;6:13-8.PMID:22291466.
SoiferHS,SouleimanianN,WuS,etal.DirectregulationofandrogenreceptoractivitybypotentCYP17inhibitorsinprostatecancercells.JBiolChem.2012Feb3;287(6):3777-87.PMID:22174412.
